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This Article considers how medical technologies impact universality in
health care. The universality principle, as embodied in the Patient Protection
and Affordable Care Act (A CA), eliminated widespread discriminatory practices
and provided financial assistance to those otherwise unable to become insured-
a democratizing federal act that was intended to stabilize health care policy
nationwide. This Article posits that medical technology, as with all of medicine,
can be universalizing or exclusionary and that this status roughly correlates to
its being "instrumental technology" or "transformative technology."
Instrumental technology acts as a tool of medicine and often serves an existing
aspect of health care; in contrast, transformative technology is pioneering,
meaning it creates a new form of care or otherwise is novel. Instrumental and
transformative medical technologies provide end points on a continuum, which
provides a lens through which to examine whether medical technology has
greater potential to facilitate universality or exclusion. The Article first
examines where technologies fit on the instrumental-transformative continuum
and then considers measures more specific to universality, namely improving the
quality of medical care, access to care, or the cost of care. These considerations
help to pinpoint the moment at which a technology may have a universalizing
effect, if at all. The Article concludes with preliminary thoughts regarding
whether the instrumental-transformative continuum helps to determine whether
certain technologies should be adopted or supported publically or allowed to
develop (or fail) organically.
* Ashland-Spears Distinguished Research Professor of Law, University of Kentucky;
Bioethics Associate, University of Kentucky College of Medicine. Thanks to Frank Pasquale and
Nicolas Terry for very helpful feedback. Thanks always DT and SRHT.
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I. INTRODUCTION
Technology can have a democratizing effect,1 increasing access
to information, demystifying knowledge or goods that were
unobtainable, and facilitating societal, vocational, and other advances
for both individuals and the collective.2 But technology also can be
costly and power entrenching and, thus, inequitable and elitist.3 Like
technology, American health care contains dichotomous tensions: on
one hand, having a long history of excluding the poor and those who
could not pursue private contracts with doctors;4 and on the other,
achieving some balance through inclusive acts of charity or public
programs that have facilitated health care access for those who could
1. The basic definition of "democratize" includes the following: "to make (something)
available to all people: to make it possible for all people to understand (something)."
Democratize, MERRIAM WEBSTER DICTIONARY, http://www.merriam-webster.com
/dictionary/democratize [https://perma.cc/2N58-HRPA] (last visited Jan. 12, 2017). The Internet
has been described as democratizing within the context of communication and, more specifically,
communication that leads to political participation and change. See, e.g., MATTHEW HINDMAN,
THE MYTH OF DIGITAL DEMOCRACY 5-6 (2008) (attempting to define normatively and
descriptively what it means for the internet to be democratizing and refuting the assumption
that the internet is inherently a positive political element).
2. See generally ANDREW FEENBERG, QUESTIONING TECHNOLOGY (1999).
3. See id. One popular theory holds that technology has power to "disrupt" medicine
and revolutionize it in a positive way. See generally CLAYTON M. CHRISTENSEN, JEROME H.
GROSSMAN & JASON HWANG, THE INNOVATOR'S PRESCRIPTION: A DISRUPTIVE SOLUTION FOR
HEALTH CARE (2009) [hereinafter THE INNOVATOR'S PRESCRIPTION] (asserting that technology
will "disrupt" traditional medical care, building on the theories delineated in Clayton M.
Christensen's The Innovator's Dilemma). This Author does not adopt this viewpoint, in part
because Christensen's theory holds that market disrupters are usually rival, low cost, low quality
"technologies" that displace existing higher quality products. In medicine, new medical
technology is often high tech-costly, experimental in nature, and new, and it is often
inaccessible or impractical for most daily medical needs. In other words, it is outside of
Christensen's business model. For a pithy, scathing review of The Innovator's Prescription, see
J.D. Kleinke, Perfection in Power Point, 28 HEALTH AFF. 1223 (2009). (Thanks to Frank Pasquale
for the pointer).
4. Nicole Huberfeld, The Universality of Medicaid at Fifty, 15 YALE J. HEALTH POL'Y L.
& ETHICS 67, 70-71 (2015) (detailing the fragmented and exclusionary nature of health care in
the United States).
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not afford it.5 The conflicting forces in technology, in many ways,
mirror conflicts within healthcare itself; medical technology can
facilitate universality or exclusion, democratization or inequity.
Medical technologies are wildly varied and can be found in
every aspect of medical practice, biomedical research, and public
health-touching healthcare finance, individual and collective care,
and engaging with laws throughout our federalist scheme. From a
treatment perspective, doctors and medical institutions regularly use
medical technologies in the curative setting.6 From a governance and
finance perspective, the federal government has established support
for medical technologies through various executive7 and legislative8
mechanisms. In addition, states regularly employ medical
technologies ranging from mundane tasks, such as enrolling
Medicaid-eligible citizens,9 to significant tasks, such as collecting and
assessing data for statewide medical trends.10
5. See, e.g., Medicaid Act, 42 U.S.C. § 1396 (2012) (providing a system of federally
funded medical assistance for low income individuals); Emergency Medical Treatment and Labor
Act, 42 U.S.C. § 1395dd (2012) (requiring screening and treatment or appropriate transfer for
any individual who seeks care at an emergency department regardless of ability to pay).
6. See, e.g., Neda Ratanawongsa et al., Association Between Clinician Computer Use
and Communication with Patients in Safety-Net Clinics, JAMA INTERNAL MED. (Nov. 15, 2015),
http://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2473628 [https://perma.ce
/3V8F-VSEY] (discussing the use of computers during patient interactions as negatively
impacting patients' perceptions of the quality of their care).
7. Robert Pear, U.S. to Collect Genetic Data to Hone Care, N.Y. TIMES (Jan. 30, 2015),
http://www.nytimes.com/2015/01/31/us/obama-to-unveil-research-initiative-aiming-to-develop-
tailored-medical-treatments.html?_r=O [https://perma.cc/9A4J-F525] (describing President
Obama's "precision medicine initiative").
8. See, e.g., Medicare Access and CHIP Reauthorization Act, Pub. L. No. 114-10, 129
Stat. 87, 97 (2015) (encouraging the use of telehealth to share patient information by deeming it
a "clinical practice improvement activity"); Patient Protection and Affordable Care Act, Pub. L.
No. 111-148, 124 Stat. 119 (2010) (deeming telehealth the equivalent of face-to-face encounters
with physicians throughout the statute); see also Health Information Technology for Economic
and Clinical Health Act, Title VIII of the American Recovery and Reinvestment Act of 2009, Pub.
L. No. 111-5, §§ 3011, 4101, 13001, 123 Stat. 115 (2009) (supporting adoption of EMR). The ACA
codified support for telemedicine in particular. See, e.g., 42 U.S.C. § 254c-18(a) (2012) ("The
Secretary may make grants to State professional licensing boards to carry out programs under
which such licensing boards of various States cooperate to develop and implement State policies
that will reduce statutory and regulatory barriers to telemedicine."); see also DEP'T OF HEALTH
AND HUMAN SERV., 2001 TELEMEDICINE REPORT TO CONGRESS (2001),
http://armtelemed.org/resources/24-USDHHSTM report-to-congress_2001.pdf [https:f/perma.cc
/PKB5-YP5H].
9. See, e.g., Medicaid Program; Mechanized Claims Processing and Information
Retrieval Systems, 80 Fed. Reg. 75817 (Dec. 4, 2015), http://www.gpo.gov/fdsys/pkg/FR-2015-12-
04/pdfl2015-30591.pdf (increasing and making permanent federal funding for states to use
information technology to administer Medicaid eligibility and enrollment); Optimizing Medicaid
Enrollment: Spotlight on Technology, HENRY J. KAISER FAM. FOUND. (July 30, 2010),
http://kff.org/health-reform/report/optimizing-medicaid-enrollment-spotlight-on-technology/
[https://perma.cc/9TFF-VLYB] (observing that the ACA increased pressure for administrative
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Given medical technologies' diversity and pervasiveness, it is
challenging to articulate one satisfying answer to questions posed by
this symposium, which assumed that technology must have a positive
impact on medicine ("Prognosis Positive: The Revolutionary Impact of
Technology on Healthcare")." Technology is not, however, always a
positive force in medicine or anywhere else.
Thus, this Article will address a topic adjacent to the writing of
medical technology experts.12  Rather than address the value of
medical technology on its own terms, this Article considers whether
medical technologies facilitate or hinder the new principle of
universality in health care. The norm of universality was enacted as
federal policy through the Patient Protection and Affordable Care Act
(ACA), 13 and it is an especially important principle for low-income
Americans, whose interests historically were not well represented in
medicine, health care law, or health care policy. 14 The universality
principle presented a new trajectory that made all Americans
insurable and able to obtain insurance.15 Universality ended reliance
on individual qualifiers, such as individual risk rating, parental
status, and income, and is grounded by leveling concepts, such as
required community rating in private insurance and open eligibility
for Medicaid in public insurance.16 The ACA eliminated widespread
discriminatory practices and provided financial assistance to those
otherwise unable to become insured-a democratizing federal act that
was intended to set the tone for health care policy nationwide.17
This Article posits that medical technology can be
universalizing or exclusionary and that this status roughly correlates
to being called "instrumental technology" or "transformative
simplicity and streamlining in Medicaid enrollment and providing links to states' experiments
using technology to improve enrollment efforts).
10. See Interactive State Report Map, APCD COUNCIL,
https://www.apedcouncil.org/state/map [https://perma.ccl6EU8-FS6S] (last visited Dec. 3, 2015).
Whether this type of data collection can be required of all health insurers, including self-insured
employers, was decided by the Supreme Court. SeeGobeille v. Liberty Mut. Ins. Co., 136 S. Ct.
936, 947 (2016) (states' all-payer claims databases are preempted by ERISA when self-insured
employers are required to submit information like any other insurer).
11. Symposium, Prognosis Positive: The Revolutionary Impact of Technology on
Healthcare, 19 VAND. J. ENT. & TECH. 101 (2016).
12. This Author would like to convey that she is not a medical technology expert.
13. Patient Protection and Affordable Care Act, 124 Stat. 119; see Huberfeld, supra note
4, at 68.
14. See Huberfeld, supra note 4, at 68.
15. See id.
16. See id. at 68; Nicole Huberfeld & Jessica Roberts, Health Care and the Myth of Self
Reliance, 57 B.C. L. REv. 1 (2016) (discussing the leveling aspects of the ACA).
17. See Huberfeld, supra note 4, at 69, 73.
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technology,"1 8 which this Article explains for the first time. This
Article defines instrumental technology as technology that acts as a
tool of medicine and often serves an existing aspect of health care.
Instrumental technology can generally be thought of as a means to an
end. In contrast, this Article defines transformative technology as
technology that is radical or pioneering, meaning it creates a new
service or device or otherwise is novel in approach or in reach.19
Instrumental and transformative medical technologies provide two
end points on a continuum rather than opposing sides of a bright line,
reflecting the changeable quality of technology itself.
This spectrum provides a lens through which to examine
whether medical technology has greater potential to facilitate
universality or exclusion in health care. Given the strong principle of
universality now underlying health care finance and access, the
question is what role medical technologies play relative to the rest of
health care in a post-ACA world. Arguably, the most common form of
government support for medical care is funding, which can facilitate
new technologies and the dispersal of established technologies.20 The
ACA indicates that both private and public insurance now cover all
lives, but this also means making harder choices in terms of
supporting more expensive or experimental technologies through
health care finance.21 Regulatory schemes can also direct medical
18. Professor Christensen uses the terms "disruptive innovation" and "sustaining
innovation" to describe the effect of breakthroughs in the business world that "disrupt" the
market of existing, successful businesses. This Author is not interested in invoking that
distinction, which does not get at the heart of this Article. Here, the Author is interested in what
medical technology does as it organically morphs from transformative to instrumental and
whether it makes medicine more or less democratic. This Author does not agree with the
assertions in The Innovator's Prescription that the market will cure all medical delivery and
accessibility issues if only innovation is allowed to disrupt the overly regulated marketplace. See
generally, THE INNOVATOR'S PRESCRIPTION, supra note 3.
19. This is a broader concept than transformative drugs, which seems to mean "offering
substantial improvements in patient outcomes over existing therapeutics." Shuai Xu & Aaron S.
Kesselheim, Medical Innovation Then and Now: Perspectives of Innovators Responsible for
Transformative Drugs, 42 J.L. MED. & ETHICS 564 (2014).
20. Unsurprisingly, when Medicare decides to pay for a new item or service, private
insurers often follow that lead, which in turn increases access to that new technology. See, e.g.,
Julia Adler-Milstein, Joseph Kvedar & David W. Bates, Telehealth Among US Hospitals: Several
Factors, Including State Reimbursement and Licensure Policies, Influence Adoption, 33 HEALTH
AFF. 207 (2014), http://content.healthaffairs.org/content/33/2/207.short.
21. See JAMES C. ROBINSON, PURCHASING MEDICAL INNOVATION: THE RIGHT
TECHNOLOGY FOR THE RIGHT PATIENT, AT THE RIGHT PRICE 14 (2015) (suggesting that insurers
should rely more on physician discretion, and that they should err on the side of encouraging
"conservative rather than aggressive use" of new technologies in medicine).
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technology by shuttling it into a distribution path, which in turn can
impact access.2 2
In Part I, this Article will examine where technologies fit on
the instrumental-transformative continuum. Part II will consider
measures more specific to universality, namely improving the quality
of medical care, access to care, or the cost of care. These bedrock
considerations for improving health care help to pinpoint the moment
at which a technology may have a universalizing effect, if at all. Part
III concludes with preliminary thoughts on how the
instrumental-transformative continuum may help to determine
whether certain technologies should be adopted or supported
publically or allowed to develop organically in more Darwinian private
markets.
II. A CONCEPT OF INSTRUMENTAL AND TRANSFORMATIVE
TECHNOLOGIES
Instrumental and transformative technologies exist throughout
the health care industry and include numerous items and services.
These include telemedicine,23 electronic medical records (EMR),
22. For example, categorizing a new drug as available only by prescription limits access
to the drug, and typically increases its cost, but classifying it as over-the-counter increases access
and decreases cost (thanks to Nicolas P. Terry for the example).
23. The Centers for Medicare and Medicaid Services (CMS) defines telemedicine thus:
For purposes of Medicaid, telemedicine seeks to improve a patient's health by
permitting two-way, real time interactive communication between the patient, and
the physician or practitioner at the distant site. This electronic communication means
the use of interactive telecommunications equipment that includes, at a minimum,
audio and video equipment. Telemedicine is viewed as a cost-effective alternative to
the more traditional face-to-face way of providing medical care (e.g., face-to-face
consultations or examinations between provider and patient) that states can choose to
cover under Medicaid. This definition is modeled on Medicare's definition of telehealth
services (42 C.F.R. § 410.78). Note that the federal Medicaid statute does not
recognize telemedicine as a distinct service.
Telemedicine, MEDICAID.GOV, http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-
Topics/Delivery-Systems/Telemedicine.html [https://perma.cc/AW9X-KHL3] (last visited Dec. 1,
2016).
CMS distinguishes telehealth:
Telehealth (or Telemonitoring) is the use of telecommunications and information
technology to provide access to health assessment, diagnosis, intervention,
consultation, supervision and information across distance.
Telehealth includes such technologies as telephones, facsimile machines, electronic
mail systems, and remote patient monitoring devices, which are used to collect and
transmit patient data for monitoring and interpretation. While they do not meet the
Medicaid definition of telemedicine they are often considered under the broad
umbrella of telehealth services. Even though such technologies are not considered
"telemedicine," they may nevertheless be covered and reimbursed as part of a
Medicaid coverable service, such as laboratory service, x-ray service or physician
services...
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electronic health records (EHR), 24 and other health information
technology (HIT). 25  Other common technologies include mobile
health,26 health insurance exchanges (HIX), 27 big data,28 and
diagnostic and therapeutic technologies, including medical devices,
biologics, cell therapies, and other alterations to the human body or its
components.29 This diverse inventory reflects medical technologies'
quick infiltration of the health care industry in recent history.
Many of the items and services listed in the prior paragraph
started as transformative and have become instrumental over time.
Transformative technologies, given their novelty, are likely to be
Id.; see also Bill Marino, Roshen Prasad & Amar Gupta, A Case for Federal Regulation of
Telemedicine in the Wake of the Affordable Care Act, 16 COLUM. Scl. & TECH. L. REV. 274, 277
(2015) (defining telemedicine as "the treatment of patients by doctors remotely, with the aid of
technology" and advocating for federal law to facilitate its uniform growth).
24. According to the Department of Health and Human Services' Office of the National
Coordinator for Health Information Technology (ONC), EMR is a narrower concept than EHR.
See Peter Garrett & Joshua Seidman, EMR us EHR - What Is the Difference?, HEALTHITBUzz
(Jan. 4, 2011), http://www.healthit.gov/buzz-blog/electronic-health-and-medical-records/emr-vs-
ehr-difference/ [https://perma.cc/68UX-QN3V ] (defining EMR as the patient's medical record, the
same information that physicians have always logged upon evaluating a patient but electronic
rather than paper, whereas EHR embodies a broader concept of record keeping and sharing). For
simplicity's sake, this Author will use the term EHR in this Article to refer to both EMR and
EHR.
25. Frank Pasquale, Grand Bargains for Big Data: The Emerging Law of Health
Information, 72 MD. L. REV. 682, 687 (2013) (calling for a new field of health information law to
develop); see also Mark A. Rothstein & Gil Siegal, Health Information Technology and
Physicians'Duty to Notify Patients of New Medical Developments, 12 HOUS. J. HEALTH L. & POL'Y
93, 103-06 (2012) (discussing forms of HIT and how HIT can make the physician's duty to warn
more readily executable); Nicolas P. Terry, Meaningful Adoption: What We Know or Think We
Know About the Financing, Effectiveness, Quality, and Safety of Electronic Medical Records, 34 J.
LEGAL MED. 7, 8 (2013) (describing EMR as a facet of HIT); Nicolas P. Terry, Information
Technology's Failure to Disrupt Health Care, 13 NEV. L.J. 722, 723 (2013) (analyzing why health
information technology and technology in general have been slow to catch on in medicine).
26. Nathan Cortez, The Mobile Health Revolution?, 47 U.C. DAVIS L. REV. 1173, 1173
(2014) (describing the phenomenon of mobile health, sounding a cautionary note, and calling for
greater oversight).
27. See, e.g., 78 Fed. Reg. 8538 (Feb. 6, 2013) (publishing notice of new system of
"records titled, 'Health Insurance Exchanges (HIX) Program,' to support the CMS Health
Insurance Exchanges Program established under provisions of the Affordable Care Act. . . ").
28. See John D. Halamka, Early Experiences with Big Data at an Academic Medical
Center, 33 HEALTH AFF. 1132 (2014) (defining big data as "a large collection of disparate data
sets that, taken together, can be analyzed to find unusual trends"); see also Barbara J. Evans,
Much Ado About Data Ownership, 25 HARV. J.L. & TECH. 69, 77 (2011) (considering the
propertization of data and weighing individual against collective interests in big data); John G.
Francis & Leslie Francis, Introduction: Technology and New Challenges for Privacy, 45 J. Soc.
PHIL. 291 (2014) (discussing privacy and confidentiality issues that arise in collecting large sets
of data from patients and advocating for the ethical principle of justice to be incorporated into big
data collection and use); Mark A. Rothstein, Ethical Issues in Big Data Research, 43 J.L. MED. &
ETHICS 425 (2015) (building on this definition of big data to draw an ethical analogy to
traditional biomedical research).
29. See generally W. Nicholson Price, II, Black-Box Medicine, 28 HARV. J.L. & TECH. 419
(2015) (discussing the high technology advances in medicine that allow personalization).
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expensive and available only to the privileged.30 The more pervasive a
medical technology becomes, the greater access it may both experience
and create, indicating that a relationship exists between the
instrumentalization of a technology and its democratization. In other
words, technologies that begin as transformative and exclusive can
become instrumental and universalizing.
Consider examples from the aforementioned medical
technologies to illustrate the above point. When telemedicine was
introduced, it was radical in concept and in execution. Video
conferencing was the stuff of science fiction; it was expensive and
unobtainable except for those with the best computers and related
equipment, including connected video cameras and relatively fast
forms of early Internet connections. Monitoring patients' vital signs
from afar was nearly impossible. Medical images, such as ultrasounds
or x-rays, could only be seen in person, typically on film, and sharing
images meant mailing a hard copy from one office or hospital to
another. Now, in contrast, video conferencing is regularly used in
homes and businesses across the nation and the world, frequently
through inexpensive or free conferencing services.31 Most mobile
phones and computers contain a built-in camera as a standard
feature, and wireless connection to the internet is freely available in
many public spaces and is relatively cheap in homes and businesses.
Medical images are digitized and often transmitted from one computer
terminal, tablet, or mobile device to another; the "internet of things"
increases and extends this connectivity.32
Each of these technological advances facilitated the three most
common uses of telemedicine: teleconferencing as a form of office visit,
monitoring chronic conditions and medical compliance, and
transmitting images or data.33 Each of these actions is a common
30. See, e.g., Daniel Callahan, Health Care Costs and Medical Technology, in FROM
BIRTH TO DEATH AND BENCH TO CLINIC: THE HASTINGS CENTER BIOETHICS BRIEFING BOOK FOR
JOURNALISTS, POLICYMAKERS, AND CAMPAIGNS 79-82 (Mary Crowley ed., 2008) (explaining why
medical technology increases medical costs); R. Krishna Kumar, Technology and Healthcare
Costs, 4 ANNALS OF PEDIATRIC CARDIOLOGY 84 (2011) (arguing that technology increases health
care costs and is not accessible to many patients).
31. See What About Telemedicine?, AM. TELEMEDICINE ASS'N,
http://www.americantelemed.org/about/about-telemedicine [https://perma.cc/2K3E-SSWQ] (last
visited Oct. 26, 2016).
32. See Daniel Burrus, The Internet of Things Is Far Bigger Than Anyone Realizes,
WIRED, http://www.wired.com/insights/2014/1 /the-internet-of-things-bigger/ [https://perma.cc
/R6X8-9MPJ] (last visited Oct. 26, 2016) (discussing how the "internet of things" works and how
extensive its connections and uses could be).
33. See Lisa Schmitz Mazur & Amy Gordon, Is Telemedicine the Potential Solution to
the Looming 'Cadillac Tax' and to Improving Employee Health?, 24 BNA HEALTH L. REP. 1682
(2015) (discussing employer use of the three aspects of telemedicine to keep costs lower than the
"Cadillac tax" trigger point).
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medical service, extended by the instrument of telemedicine.
Telemedicine enhances a doctor or nurse's reach and is a provider's
tool for offering skills and services; it is widely available throughout
the nation, reimbursed by public and private insurers, and
inexpensive to use.34 The most common telemedicine services are
reimbursed by Medicare and Medicaid, a fact that offers indirect
evidence of common acceptance in medical practice and supports the
notion that telemedicine has transitioned from a transformative to an
instrumental technology.35
Consider a second example, EHR, which has an arc similar to
telemedicine's. HIPAA is thought of as a privacy law, but its original
objective was to construct national standards for portability of health
insurance from one job to the next and electronic exchange of health
insurance forms.36  In 1996, the technology to create electronic
exchange of health insurance forms was expensive and largely
elusive: email was not routine, computers were not pervasive, and
Internet connectivity was slow or unavailable. Fast forward to 2016,
when the equipment has become commonplace. Virtually all
businesses and many homes contain computers, and many doctors and
hospitals use computers or tablets for tracking patient data and
accessing reference materials.37  In 2009, Congress created new
34. See, e.g., Steff Deschenes, Five Ways Telemedicine Is Driving Down Healthcare Costs,
HEALTHCAREITNEWS (July 16, 2012, 10:29 AM), http://www.healthcareitnews.com/news/5-ways-
telemedicine-driving-down-healthcare-costs [https://perma.cc/XXJ3-2LLD]; Laurence C. Baker et
al., Integrated Telehealth and Care Management Program for Medicare Beneficiaries with
Chronic Disease Linked to Savings, 30 HEALTH AFF. 1689 (2011).
35. See 42 C.F.R. § 410.78 (defining telehealth services that Medicare will reimburse);
Centers for Medicare and Medicaid Services, Telemedicine, MEDICAID.GOV,
https://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Delivery-
Systems/Telemedicine.html [https://perma.cc/LJ8M-BWTC] (last visited Jan. 15, 2016)
(explaining telehealth and Medicaid's reliance on Medicare's definitions of telehealth). CMS
states, "Note that the federal Medicaid statute does not recognize telemedicine as a distinct
service." Id. CMS considers telemedicine and telehealth to be related but different services.
36. Health Insurance Portability and Accountability Act, Pub. L. No. 104-91 (1996); 45
C.F.R. §§ 164.500-164.534 (2009); Nicolas P. Terry, What's Wrong with Health Privacy?, 5 J.
HEALTH & BIOMEDICAL L. 1 (2009) (detailing HIPAA's history and attendant problems).
37. An important exception is low-income individuals; research shows that people earning
the least are also the least likely to have access to the Internet or to own home computers, a
phenomenon called the "digital divide." See Kathryn Zickuhr & Aaron Smith, Digital Differences,
PEW RES. CTR. (Apr. 13, 2012), http://www.pewinternet.org/2012/04/13/digital-differences/
[https://perma.cc/53DJ-HP92). That report noted that the digital divide is changing because
internet access is not tied to computer ownership like it was fifteen years ago. The report stated
internet access is no longer synonymous with going online with a desktop computer:
Currently, 88 percent of American adults have a cell phone, 57 percent have
a laptop, 19 percent own an e-book reader, and 19 percent have a tablet
computer; about six in ten adults (63 percent) go online wirelessly with one
of those devices. Gadget ownership is generally correlated with age,
education, and household income, although some devices-notably e-book
275
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financial incentives to encourage EHR adoption and interoperability
standards, implicitly recognizing that the technology that facilitates
EHR has moved from transformative to instrumental over the last
twenty years.38
Telemedicine and EHR sit on the instrumental end of the
medical technology spectrum. They exhibit key features: they are not
experimental, not radical, and not expensive to execute. They are
common technologies that are easily accessed or easily constructed for
those who want to use them. They contain some start-up costs, but
their costs typically dissipate on a short time horizon. They facilitate
access to health care and communication between and among health
care providers and patients.
Consider a third example that sits closer to the middle of the
spectrum: the federal and state HIX created by the ACA. HIX are
similar to travel websites that search airlines for a particular flight
path or hotels for open rooms on certain dates and times, but the
industry underlying HIX is more complex and highly regulated.39 HIX
are not typically considered medical technology. Given their use of
computer technology to create and facilitate access to health insurance
through digital clearinghouses, however, HIX fit under the medical
technology umbrella as a form of modern technology that has the
power to increase health insurance enrollment, which in turn could
improve access to care.
The task of building the HIX was substantial, and it cost the
federal government hundreds of millions of dollars to implement its
own exchange and to encourage states to create theirs.40 Some states
readers and tablets-are as popular or even more popular with adults in
their thirties and forties than young adults ages 18-29.
* The rise of mobile is changing the story. Groups that have traditionally been
on the other side of the digital divide in basic internet access are using
wireless connections to go online. Among smartphone owners, young adults,
minorities, those with no college experience, and those with lower household
income levels are more likely than other groups to say that their phone is
their main source of internet access.
* Even beyond smartphones, both African Americans and English-speaking
Latinos are as likely as whites to own any sort of mobile phone and are more
likely to use their phones for a wider range of activities.
Id.
38. Health Information Technology for Economic and Clinical Health Act, Title XIII of
American Recovery and Reinvestment Act of 2009, Pub. L. No. 111-5.
39. See HEALTHCARE.Gov, https://www.healthcare.gov (last visited Oct. 26, 2016).
Common examples include EXPEDIA, https://www.expedia.com (last visited Oct. 26, 2016) and
TRAVELOCITY, https://travelocity.com (last visited Oct. 26, 2016).
40. The cost of the federal exchange is difficult to pin down, but one source indicates
$834 million as of February 2014. See Testimony of Sylvia M. Burwell, Nominee for Secretary of
United States Department of Health and Human Services: Hearing on the Nomination of the
Secretary of Health and Human Services-Designate, Sylvia Matthews Burwell Before the S.
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failed, and some did not choose to create their own exchanges.41 The
difficult start was not because the technology itself was
transformative-this kind of database was transformative a decade
ago when Massachusetts originated statewide universal health
insurance coverage and created the "Connector," a predecessor to
HIX. 42 Rather, the work was substantial because the elements of the
HIX existed in one state under that state's particular regulatory
regime, and other governmental actors had not created this type of
database with federal regulatory elements before the ACA. 4 3
Gathering and compiling the qualified health plans in one place,
on-line, meeting all regulatory standards and being able to screen all
purchasers for their individual qualifications (i.e., eligibility for tax
credits or for Medicaid), was a large task, but transformative only in
terms of purchasing health insurance. The philosophy behind
creating HIX, allowing direct governmental intervention in private
insurance markets, could be deemed transformative, but that is a
function of the law rather than technology. In other words, the
technology itself was not transformative. HIX is instrumental
technology that enables universal health insurance coverage, which is
a transformative health policy concept, but not transformative medical
technology. It is a tool for health insurance regulatory and purchasing
mechanisms, not a novel technology that alters medical items or
services.
The three prior examples illustrate elements of instrumental
medical technology. An example of transformative technology aids in
finding the other end of the spectrum. Consider gene therapy, a
highly specialized, complex procedure that provides individualized
treatment and has the potential to treat diseases deemed incurable by
Comm. on Health, Educ., Labor and Pensions, 113th Cong. (2014) (testimony of Sylvia Matthews
Burwell, Nominee for Secretary United States Department of Health and Human Services).
41. The federal government offered states grants to create their own exchanges, and some
states floundered at the opening of their exchanges for January 1, 2014 implementation of the
ACA's insurance precepts. See, e.g., Kyle Cheney & Jennifer Haberkorn, $474M for 4 Failed ACA
Exchanges, POLITICO (May 30, 2014), http://www.politico.com/story/2014/05/obamacare-cost-
failed-exchanges-106535 [https://perma.cc/X5KJ-6B7W] (discussing the failed opening of the
Massachusetts, Oregon, Nevada and Maryland exchanges; Oregon has switched to the federal
exchange, but the other states made their exchanges work).
42. See History: Massachusetts: The Model for National Health Care Reform, MASS.
HEALTH CONNECTOR, https://www.mahealthconnector.org/about/policy-center/history
[https://perma.cc/XS6U-TSME] (last visited Oct. 26, 2016); see also State Marketplace Profiles:
Massachusetts, HENRY J. KAISER FAM. FOUND., http://kff.org/health-reform/state-profile/state
-exchange-profiles-massachusetts [https://perma.cc/9FBL-VQ7D ] (last visited Oct. 26, 2016)
(describing the Massachusetts Connector as the model for the federal HIX).
43. The Massachusetts Health Connector was established by Massachusetts law in
2006. See History: Massachusetts: The Model for National Health Care Reform, supra note 42.
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altering mutated genes in an individual.4 4  Gene therapy suffered
biomedical and ethical setbacks in its earliest stages.4 5 Despite nearly
two decades of research, gene therapy remains far from being a real
treatment option for most of the population and is still considered
experimental.4 6 It is prohibitively expensive; only patients with the
best, most advanced care and the greatest ability to pay for medical
expenses can obtain it, unless patients are willing to participate as
subjects in a research trial.4 7 Companies that own the rights to gene
therapies are setting the price for treatment as high as one million
dollars.4 8  Even if payments were spread over time, the average
American could not afford it. Health insurers tend to plan on short
timelines assuming that most enrollees will be in a new plan within a
few years, classically called the "revolving door" of health insurance.4 9
This mindset would bar payment for such costly, individualized
treatments, even if an insurer is paying hundreds of thousands of
dollars for other forms of care for chronically ill individuals. Medicare
and Medicaid may pay for some genetic testing, if related to
determining the best course of treatment for, say, a person with
genetically inherited cancer, but public health care programs do not
reimburse gene therapy.50
Though a somewhat extreme example, gene therapy helps to
tease out features of transformative medical technologies. Such
features include: the technology is radically different from existing
therapies, drugs, or other medical items and services; it may treat
inherited orphan diseases (such as thalassemia) or otherwise
untreatable inherited diseases or conditions (such as hemophilia or
44. See What Is Gene Therapy?, NAT'L INST. OF HEALTH NAT'L LIBR. OF MED.,
https://ghr.nlm.nih.gov/primer/therapy/genetherapy [https://perma.cc/QUS4-YKQK] (last visited
Oct. 25, 2016).
45. See, e.g., Carolyn Y. Johnson & Brady Dennis, Gene Therapies Offer Dramatic Promise
but Shocking Costs, WASH. POST (Nov. 11, 2015), https://www.washingtonpost.com
/business/economy/gene-therapies-offer-dramatic-promise-but-shocking-costs/2015/11/11/01f11cf0
-824b-11e5-9afb-Oc97f7l3dOc-story.html?hpid=hp-rhp-more-top-stories-no-name%3Ahomepage
%2Fstory [https://perma.cc/FWQ6-CNJM] (reporting some gene therapies could cost in the
millions of dollars).
46. What Is Gene Therapy?, supra note 44.
47. See Johnson & Dennis, supra note 45.
48. Chris Morrison, $1-Million Price Tag Set for Glybera Gene Therapy, NATURE.COM
(Mar. 3, 2015, 12:32 AM,) http://blogs.nature.com/tradesecrets/2015/03/03/1-million-price-tag-set
-for-glybera-gene-therapy [https://perma.cc/6QFZ-4T7D] (discussing prices being set for new gene
therapies).
49. See, e.g., R.O. Morgan et al., The Medicare-HMO Revolving Door--The Healthy Go in
and the Sick Go Out, 337 NEW ENG. J. MED. 169 (1997).
50. See STUART WRIGHT, COVERAGE AND PAYMENT FOR GENETIC LABORATORY TESTS, OEI-
07-11-00011, at 2 (2012), http://oig.hhs.gov/oeilreports/oei-07-11-00011.pdf [https://perma.cc
/2K95-KZFL].
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certain cancers); or it may facilitate understanding medical
information that was indecipherable before the technology existed (big
data). The cost of transformative medical therapies is generally high,
and insurers almost certainly consider them experimental and thus
excluded from coverage.
One way to think about medical technologies' role in universal
health coverage is to place them on the instrumental-transformative
continuum. This brief discussion highlighted the potential for
transformative technologies to become instrumental and the difference
between the two. It also indicated that instrumental technologies are
more likely to be universalizing because they are easy to access,
inexpensive, and facilitate better care. In short, instrumental
technologies tend to facilitate universality, while transformative
technologies tend to be exclusionary by virtue of their cost, complexity,
and general inaccessibility. The hardest question may be when the
tipping point occurs between the two.
III. UNIVERSALITY AND MEDICAL TECHNOLOGY
Universality can emerge through different dimensions of
health care, such as improving the quality of medical care, expanding
access to medical care, or decreasing the cost of care for large portions
of the population. The ACA attempts all of these improvements to
American health care, though arguably the greatest effort is spent on
increasing access to care through universal insurance coverage.51
Medical technologies could fit within this set of measures by
decreasing the invasiveness of a widely used treatment, preventing or
treating conditions that affect wide swaths of the population,
improving quality of life for individuals with chronic conditions, or
improving access for those with difficulty finding medical care in a
geographic location.
The question is whether to encourage or support medical
technologies given that cost is always a concern in health care-and
perhaps even more so in the era of universal coverage.52  If
technologies should be encouraged, a straightforward mechanism for
policy entrenchment exists in the Spending Power, one of Congress's
51. See Huberfeld & Roberts, supra note 16, at 3.
52. See generally Ann Marie Marciarille & J. Bradford DeLong, Bending the Health Cost
Curve: The Promise and Peril of the Independent Payment Advisory Board, 22 HEALTH MATRIX:
J.L. & MED. 75 (2012) (discussing the fact that the cost of health care is a longstanding policy
concern in the United States); see also Reed Abelson, Cost, Not Choice, Is Top Concern of Health
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most powerful tools for encouraging implementation of federal policy
goals.53 Wielding this power, Congress has created public insurance
like Medicare and Medicaid,54 facilitated employer-sponsored health
insurance coverage through tax policy, 55 encouraged development of
new drugs by providing grants for clinical research,56 facilitated family
planning through grants to clinics and health care providers,5 7 and
other far-reaching medical policies. The states, too, can encourage
developments in medical policy. For example, some states have
chosen to fund stem cell research when presidential policies dictated
otherwise.5 8 But the ACA encourages thinking broadly and nationally
about medical policy, and federal spending legislation is a principal
mechanism for such policymaking.59
A harder question is where in the transition from
transformative to instrumental funding should be wielded to support
technologies, if at all. One possibility is to evaluate the chances that
the transformative technology will become an instrumental technology
through existing channels without regulatory or financial
encouragement and to adopt such technologies when they are least
expensive and most useful to patients. Theranos, the tech start-up
that attempted to design a simplified and cheaper blood testing
mechanism, provides a recent example for considering whether
supporting transformative medical technologies holds potential for
furthering universality.
Theranos sought to create a blood test that could be conducted
at home, with a pinprick's amount of blood, that would cost a fraction
53. U.S. CONST. art. I, § 8, cl. 1.
54. 42 U.S.C. § 1395 (2012) (Medicare); 42 U.S.C. § 1396 (2012) (Medicaid).
55. Patient Protection and Affordable Care Act, Pub. L. No. 111-148, 124 Stat. 119
(2010).
56. See Funding, NAT'L INSTS. OF HEALTH, http://grants.nih.gov/funding/index.htm
[https://perma.cc/2WX4-AS5D ] (last visited Mar. 23, 2016).
57. Title X of the Public Health Service Act, Population Research and Voluntary Family
Planning Programs, Pub. L. 91-572 (1970). As HHS states, "Title X is the only federal grant
program dedicated solely to providing individuals with comprehensive family planning and
related preventive health services." History of Title X, DEP'T. OF HEALTH AND HUM. SERVS.,
http://www.hhs.gov/opa/title-x-family-planning/ [https://perma.cc/8VWP-YG65] (last visited Oct.
25, 2016).
58. JUDITH A. JOHNSON & ERIN D. WILLIAMS, STEM CELL RESEARCH: STATE INITIATIVES
2 (2006), https://stemcells.nih.gov/staticresources/researchlGW-State-Funding.pdf.
59. This is true even after National Federation of Independent Business v. Sebelius, in
which the Supreme Court, by a plurality, recognized a constitutional doctrine of coercion. 132 S.
Ct. 2566, 2602 (2012). In fact, the Court cited approvingly prior precedent upholding the
conditional spending power and delineating how it can be used. See id. Though the spending
power may be limited in other ways after NFIB v. Sebelius, it does not appear to be limited for
the policymaking purposes discussed herein. See generally Nicole Huberfeld, Elizabeth Weeks
Leonard & Kevin Outterson, Plunging into Endless Difficulties: Medicaid and Coercion in
National Federation of Independent Business v. Sebelius, 93 B.U. L. REV. 1 (2013).
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of current blood tests.60 If Theranos had achieved this mission, the
technology would have been transformative. No medical device exists
that can take a few drops of blood (as opposed to many vials) to run
the full range of laboratory diagnostics.61  Though the Theranos
technology remains elusive, and the company got into regulatory
trouble, if successful, it would have transformed the field of blood
testing, which is the lucrative backbone of most diagnostic work.62 It
would have made field testing much easier and cheaper (especially
important in the event of an epidemic), and it could have made such
private matters as testing for sexually transmitted infections easier to
perform in the privacy of the home. These would be transformative
steps in diagnostic medical technology.
Theranos also provides a cautionary tale of a transformative
technology that crashed into regulatory hurdles designed to prevent
fraud on unsuspecting consumers of medical products. The company
allegedly neglected Food and Drug Administration regulations
pertaining to medical devices, and its testing system seems to run
inaccurate laboratory results.6 3 The company's loose approach to
regulatory superstructure led the Centers for Medicare and Medicaid
Services to sanction Theranos.64 These details are headline grabbing,
but the larger question is whether existing finance mechanisms and
regulatory regimes can position technology like this to safely
transition from transformative to instrumental and thus to be
democratized.
In other words, we could ask whether the Theranos technology
will improve medical care, or access to care, or payment for care. The
answer to all three questions is yes, but only if it is assumed that
60. THERANOS, https://www.theranos.com (last visited Oct. 5, 2016).
61. Robert Parloff, This CEO Is out for Blood, FORTUNE (June 12, 2014),
http://fortune.com/2014/06/12/theranos-blood-holmes/ [https://perma.ccl7S79-USSA].
62. Reed Abelson & Julie Creswell, Theranos Founder Faces a Test of Technology, and
Reputation, N.Y. TIMES (Dec. 19, 2015), http://www.nytimes.com/2015/12/20/business/theranos-
founder-faces-a-test-of-technology-and-reputation.html [https://perma.cc/NBU4-GFKR] (detailing
the rise of Theranos and its technology's setbacks). In fact, lab testing is so lucrative that
physicians started to own clinical laboratories and refer their patients to them; concern over such
self-referrals led to passage of the Ethics in Patient Referrals Act, known commonly as the
"Stark Law." 42 U.S.C. § 1395nn (2012).
63. John Carreyrou, Hot Startup Theranos Has Struggled with Its Blood-Test Technology,
WALL ST. J. (Oct. 16, 2015, 3:20 PM), http://www.wsj.com/articles/theranos-has-struggled-with-
blood-tests-1444881901 [https://perma.cc/9QSN-74EA].
64. See Theranos and Its CEO Slapped with CMS Sanctions, GENETIC ENGINEERING AND
BIOTECHNOLOGY NEws (July 8, 2016), http://www.genengnews.com/gen-news-
highlights/theranos-and-its-ceo-slapped-with-cms-sanctions/81252928/ [https://perma.cc/D9FZ-
5Y89]; Beth Jones Sanborn, Theranos Appeals Sanctions Imposed by Centers for Medicare and
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Theranos's assertions are true. The Theranos website proclaims: "The
lab test, reinvented. We believe the future of health care lies in
greater access for the individual. So we built a better lab experience
with access in mind, making it easier than ever for you to engage with
your health early and at the time it matters most .... ."65 If accurate,
this would have provided an example of transformative technology
that could and should quickly become instrumental, which would push
toward government supports at the moment where the technology can
make that transition.
The reason for contemplating public support through funding is
that this is the type of transformative medical technology that
facilitates universality. This Article does not endorse any medical
technology specifically, but rather, considers the model of
transformative technology that such companies represent. A
transformative technology that changes a fundamental aspect of basic
medical diagnostics-making it easier on the patient in terms of pain,
time, and cost, less expensive for payors, and easier for doctors to
obtain key diagnostic information-is the kind of transformative
technology that could quickly become instrumental and would serve
the goals of universality.
Knowing whether a medical technology is transformative or
instrumental can offer an indicator as to whether certain technologies
are worthy of support through finance, regulatory mechanisms, or
other forms of adoption through payment or encouragement for
innovation. An inquiry into whether the technology could improve
medical care, access to care, or payment for care helps a technology to
be more fully analyzed for its universalizing effect, which in turn could
trigger an understanding of desirable regulatory or financial
supports.66
IV. CONCLUSION
Technologically improved health care often comes at a high cost
that only increases over time;67 to be wary of medical technology is to
65. THERANOS, supra note 60.
66. See ROBINSON, supra note 21, at 9 (encouraging growth of medical technology and
innovation through four stages of value-based purchasing, "regulatory market access, insurance
coverage, care delivery, and patient engagement"). One possible model for this is the National
Institute for Health and Care Excellence, part of the British National Health Service (NHS),
which uses complex algorithms for determining whether medical technologies will be adopted by
NHS. See Guide to the Processes of Technology Appraisal, NAT'L INST. FOR HEALTH AND CARE
EXCELLENCE (Sept. 2, 2014), https://www.nice.org.uk/article/pmgl9/chapter/1-
ilntroductionPMG19 [https://perma.cc/8JKC-5Z3W].
67. Snapshots: How Changes in Medical Technology Affect Health Care Costs, HENRY J.
KAISER FAM. FOUND. (Mar. 2, 2007), http://kff.org/health-costs/issue-brief/snapshots-how-
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recognize the low benefit that many new technologies present to most
patients.6 8 Yet, as technology becomes more integral to health care,
the instrumental-transformative continuum may help dissect choices
about whether certain technologies should be adopted or supported
publically, or allowed to develop organically in more Darwinian
private markets. The substance of those technologies and the effect
they will have on quality of care, access to care, and cost of care are
important characteristics in placing technologies on the continuum
and then considering whether they can improve universal access to or
distribution of medical care in a system with limited resources and an
increased sense of broad-based policymaking.
changes-in-medical-technology-affect/ [https://perma.cclYE5S-UQE2] (discussing the tendency of
medical technology to drive costs up rather than down); Daniel Callahan, Health Care Costs and
Medical Technology, in FROM BIRTH TO DEATH AND BENCH TO CLINIC: THE HASTINGS CENTER
BIOETHICS BRIEFING BOOK FOR JOURNALISTS, POLICYMAKERS, AND CAMPAIGNS 79-82 (Mary
Crowley, ed. 2008), http://www.thehastingscenter.org/uploadedFiles/Publications
/BriefingBook/health%20care%20costs%20chapter.pdf (ascribing steadily increasing costs of
medical care to medical technology); Corinna Sorenson, Michael Drummond & Beena Bhuiyan
Khan, Medical Technology as a Key Driver of Rising Health Expenditure: Disentangling the
Relationship, CLINICOECONOMICS AND OUTCOMES RES. 1223-34 (2013),
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686328/pdf/ceor-5-223.pdf [https://perma.cc
/86XA-WRC9] (refuting that all technology increases the cost of medical care and calling for a
textured consideration of the costs of medical technology).
68. See ROBINSON, supra note 21, at 2 (describing "new drugs, devices, diagnostics, and
procedures" as the root of increasing health care costs, even as they improve the quality of care).
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